@article{RackwitzEdenReppenhagenetal.2012,
  author    = {Rackwitz, Lars and Eden, Lars and Reppenhagen, Stephan and Reichert, Johannes C. and Jakob, Franz and Walles, Heike and Pullig, Oliver and Tuan, Rocky S. and Rudert, Maximilian and N{\"o}th, Ulrich},
  title     = {Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head},
  series = {Stem Cell Research \& Therapy},
  volume    = {3},
  journal   = {Stem Cell Research \& Therapy},
  number    = {7},
  doi       = {10.1186/scrt98},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-135413},
  year      = {2012},
  abstract  = {Avascular necrosis (AVN) of the femoral head is a debilitating disease of multifactorial genesis, predominately affects young patients, and often leads to the development of secondary osteoarthritis. The evolving field of regenerative medicine offers promising treatment strategies using cells, biomaterial scaffolds, and bioactive factors, which might improve clinical outcome. Early stages of AVN with preserved structural integrity of the subchondral plate are accessible to retrograde surgical procedures, such as core decompression to reduce the intraosseous pressure and to induce bone remodeling. The additive application of concentrated bone marrow aspirates, ex vivo expanded mesenchymal stem cells, and osteogenic or angiogenic growth factors (or both) holds great potential to improve bone regeneration. In contrast, advanced stages of AVN with collapsed subchondral bone require an osteochondral reconstruction to preserve the physiological joint function. Analogously to strategies for osteochondral reconstruction in the knee, anterograde surgical techniques, such as osteochondral transplantation (mosaicplasty), matrix-based autologous chondrocyte implantation, or the use of acellular scaffolds alone, might preserve joint function and reduce the need for hip replacement. This review summarizes recent experimental accomplishments and initial clinical findings in the field of regenerative medicine which apply cells, growth factors, and matrices to address the clinical problem of AVN.},
  language  = {en}
}
@article{KleinBenchellalKleffetal.2013,
  author    = {Klein, Diana and Benchellal, Mohamed and Kleff, Veronika and Jakob, Heinz G{\"u}nther and Erg{\"u}n, S{\"u}leyman},
  title     = {Hox genes are involved in vascular wall-resident multipotent stem cell differentiation into smooth muscle cells},
  series = {Scientific Reports},
  volume    = {3},
  journal   = {Scientific Reports},
  number    = {2178},
  doi       = {10.1038/srep02178},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131496},
  year      = {2013},
  abstract  = {Human vascular wall-resident CD44+ multipotent stem cells (VW-MPSCs) within the vascular adventitia are capable to differentiate into pericytes and smooth muscle cells (SMC). This study demonstrates HOX-dependent differentiation of CD44(+) VW-MPSCs into SMC that involves epigenetic modification of transgelin as a down-stream regulated gene. First, HOXB7, HOXC6 and HOXC8 were identified to be differentially expressed in VW-MPSCs as compared to terminal differentiated human aortic SMC, endothelial cells and undifferentiated pluripotent embryonic stem cells. Silencing these HOX genes in VW-MPSCs significantly reduced their sprouting capacity and increased expression of the SMC markers transgelin and calponin and the histone gene histone H1. Furthermore, the methylation pattern of the TAGLN promoter was altered. In summary, our findings suggest a role for certain HOX genes in regulating differentiation of human VW-MPSC into SMCs that involves epigenetic mechanisms. This is critical for understanding VW-MPSC-dependent vascular disease processes such as neointima formation and tumor vascularization.},
  language  = {en}
}